Neurocritical care · 2025
In vivo Testing of the Pressio Intracranial Pressure Monitor.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gergelé Laurent, Mallard Jérémy, Magand Clément, Lagarde Kevin, Chabanne Russel, Morel Jérôme, Payen Jean François, Launey Yoann
Аннотация
BACKGROUND: Measuring reliable intracranial pressure (ICP) is critical for patients with acute brain injuries. The aim of this study was to evaluate zero drift of the intraparenchymal strain gauge Pressio transducer (Sophysa, Orsay, France) in clinical conditions.
METHODS: A prospective observational multicenter study was conducted in four French intensive care units of university hospitals. Patients with acute brain injuries were included if they needed ICP measurement using the Pressio transducer. The zero drift was measured at the explantation of the sensor. ICP-related adverse events were also collected.
RESULTS: Between January 1, 2018, and March 31, 2020, 235 patients were included in this study for a monitoring time of 2,180 days. The zero drift assessment was determined in 223 transducers (95%). The median duration of ICP monitoring was 8 days (interquartile range [IQR] 4 to 13 days). The median zero drift was 1 mm Hg (IQR 1 to 3 mm Hg), and a weak correlation was observed between the duration of ICP monitoring and zero drift (ρ = 0.141; P = 0.0357), which lacks clinical significance. Zero drifts higher than 5 mm Hg were found in 10% of transducers. Four patients (1.8%) had ICP-related hematomas, with no clinical impact, and none had ICP-related brain infection. Failures or technical dysfunctions of the monitoring were found in six patients (2.6%).
CONCLUSIONS: The Pressio catheter from the Sophysa system exhibited a minor zero drift after a median monitoring period of 8 days. The transducer's precision was comparable to that of other ICP devices using strain gauge technology.
METHODS: A prospective observational multicenter study was conducted in four French intensive care units of university hospitals. Patients with acute brain injuries were included if they needed ICP measurement using the Pressio transducer. The zero drift was measured at the explantation of the sensor. ICP-related adverse events were also collected.
RESULTS: Between January 1, 2018, and March 31, 2020, 235 patients were included in this study for a monitoring time of 2,180 days. The zero drift assessment was determined in 223 transducers (95%). The median duration of ICP monitoring was 8 days (interquartile range [IQR] 4 to 13 days). The median zero drift was 1 mm Hg (IQR 1 to 3 mm Hg), and a weak correlation was observed between the duration of ICP monitoring and zero drift (ρ = 0.141; P = 0.0357), which lacks clinical significance. Zero drifts higher than 5 mm Hg were found in 10% of transducers. Four patients (1.8%) had ICP-related hematomas, with no clinical impact, and none had ICP-related brain infection. Failures or technical dysfunctions of the monitoring were found in six patients (2.6%).
CONCLUSIONS: The Pressio catheter from the Sophysa system exhibited a minor zero drift after a median monitoring period of 8 days. The transducer's precision was comparable to that of other ICP devices using strain gauge technology.